



Health-related quality of life among spondyloarthritis and chronic low back pain patients: results from a nationwide population-based survey

Helena Santos¹ · Ana Rita Henriques² · Jaime Branco² · Pedro M. Machado³ · Helena Canhão² · Fernando M. Pimentel-Santos⁴ · Ana Maria Rodrigues^{2,5}

Accepted: 6 October 2022 / Published online: 29 October 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract

Purpose Both spondyloarthritis and chronic low back pain (CLBP) significantly impact health-related quality of life (HRQoL). It is important to clarify whether these disorders have different impacts on the several domains of HRQoL as different mechanisms may necessitate different treatment interventions. Moreover, the factors associated with HRQoL can inform more targeted group interventions to promote HRQoL.

Methods We used data from EpiReumaPt, a population-based survey conducted from September 2011 to December 2013. HRQoL was assessed with EuroQoL-5-Dimensions (EQ-5D). Spondyloarthritis was diagnosed by expert opinion (rheumatologist) and predefined criteria. CLBP was diagnosed if low back pain was present on the day of the interview and persisted for > 90 days. Univariable and multivariable linear regression analyses compared HRQoL among subjects with spondyloarthritis, CLBP, and no rheumatic diseases. Multivariable linear regression analyses evaluated HRQoL factors in spondyloarthritis and CLBP subjects.

Results We included 92 spondyloarthritis patients, 1376 CLBP patients, and 679 subjects without rheumatic diseases. HRQoL was similarly affected in spondyloarthritis and CLBP ($\beta = -0.03$, 95% CI $[-0.08; 0.03]$) in all EQ5D dimensions. A much lower HRQoL was found in spondyloarthritis and CLBP patients compared with subjects without rheumatic diseases ($\beta = -0.14$, 95% CI $[-0.19; -0.10]$; $\beta = -0.12$, 95% CI $[-0.14; -0.09]$, respectively). In spondyloarthritis subjects, multimorbidity and active disease were associated with worse HRQoL ($\beta = -0.18$; 95% CI $[-0.24; 0.03]$; $\beta = -0.13$; 95% CI $[-0.29; -0.05]$, respectively), and regular physical exercise was associated with better HRQoL ($\beta = 0.18$; 95% CI $[0.10; 0.30]$). In CLBP subjects, multimorbidity ($\beta = -0.11$; 95% CI $[-0.14; -0.08]$), obesity ($\beta = -0.04$; 95% CI $[-0.08; -0.01]$), and low back pain intensity ($\beta = -0.02$; 95% CI $[-0.03; -0.02]$) were associated with worse HRQoL, and regular physical exercise ($\beta = 0.08$; 95% CI $[0.05; 0.11]$) was significantly associated with better HRQoL.

Conclusion Spondyloarthritis and CLBP subjects reported similar levels of impairment in the mental, physical, and social domains of HRQoL. Future health plans should address modifiable factors associated with HRQoL in these conditions to achieve better outcomes.

Keywords Health-related quality of life · EQ-5D · Chronic low back pain · Spondyloarthritis

✉ Helena Santos
helenasantoscc@gmail.com

Ana Rita Henriques
anarita.henriques@nms.unl.pt

Jaime Branco
jaime.branco@nms.unl.pt

Pedro M. Machado
p.machado@ucl.ac.uk

Helena Canhão
helenacanhao@gmail.com

Fernando M. Pimentel-Santos
pimentel.santos@gmail.com

Ana Maria Rodrigues
anamfrodrigues@gmail.com

¹ Nova Medical School, EpiDoc Unit/Comprehensive Health Research Center, Instituto Português de Reumatologia, Rua da Beneficência, n 7, 1050-034 Lisbon, Portugal

² Nova Medical School, EpiDoc Unit/Comprehensive Health Research Center, Lisbon, Portugal

³ Centre for Rheumatology and Department of Neuromuscular Diseases, University College of London, London, UK

⁴ Nova Medical School, CEDOC—Rheumatic Diseases Lab, Lisbon, Portugal

⁵ Hospital Dos Lusíadas, Lisbon, Portugal

Plain english summary

Spondyloarthritis and chronic low back pain are important rheumatic conditions, associated with significant disease burden, including loss of quality of life. Despite both having back pain as the main symptom, it is important to clarify whether the impact on the several domains of quality of life is different, as they may benefit from different pharmacologic and non-pharmacologic interventions depending on the specific factors that impact quality of life. In this nationwide population-based study, we have compared quality of life in subjects with spondyloarthritis, chronic low back pain, and subjects with no rheumatic and musculoskeletal disease. We have also identified factors associated with quality of life in spondyloarthritis and chronic low back pain subjects. Our study shows that spondyloarthritis and chronic low back pain subjects have a worse quality of life than subjects with no rheumatic and musculoskeletal disorders, and both show similar levels of impairment in the mental, physical, and social domains. Quality of life is associated with lifestyle modifiable factors: regular physical exercise is related to a better quality of life and multimorbidity with a worse quality of life. Findings from this study highlight the importance of addressing modifiable factors to improve quality of life in these conditions.

Introduction

Health-related quality of life (HRQoL) is a subjective assessment of the impact of a disease and its treatment [1]. It is a broad, multidimensional concept that includes patient perspectives of life's positive and negative aspects in the physical, mental, and social domains [2]. HRQoL assessment is now a mandatory aspect of disease burden evaluation, so patient-oriented treatments can be developed to promote HRQoL.

Musculoskeletal disorders are the second most common cause of disability worldwide [3, 4]. These disorders place a significant burden on patients [5–9], seeming to mainly impact the physical domain but also, to a lesser extent, the mental and social domains of HRQoL [5, 7, 9]. Moreover, musculoskeletal disorders are associated with poorer HRQoL than several other chronic medical conditions [10–14]. Within musculoskeletal disorders, lower back and neck pain are the leading global cause of disability in most countries [3, 4]. Epidemiological studies have reported a median global prevalence of low back pain of 15.0%, although there is substantial heterogeneity in the results [15]. A study in Portugal found that self-reported

low back pain was the most common rheumatic condition and that chronic low back pain (CLBP) had a national prevalence of 10.4% [16]. CLBP harms both physical and mental health [16–19], and its impact on HRQoL increases with both the duration of back pain [20] and pain severity. Irrespective of medication use [18], CLBP has been compared to the pain experienced by people diagnosed with life-threatening diseases [21].

Spondyloarthritis is a chronic inflammatory rheumatic disease affecting the axial (spine and sacroiliac joints) and peripheral skeleton; according to the cardinal manifestations of the disease, it can therefore be classified as axial [22] or peripheral spondyloarthritis [23]. Inflammatory low back pain is the most common manifestation of axial spondyloarthritis but is frequently seen in peripheral spondyloarthritis as well, and a recent study showed axial involvement in 55% of the included patients [24]. Axial and peripheral spondyloarthritis are potentially disabling conditions as the resulting inflammation and structural damage lead to pain and stiffness that can impair physical function and HRQoL [25–32].

Although both spondyloarthritis and CLBP affect the axial skeleton and share low back pain as the main symptom, they produce low back pain via different mechanisms (inflammatory vs. mechanical), leading to significant differences in treatment options. Non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and biologic treatments are recommended to reduce symptoms and improve HRQoL in spondyloarthritis [33, 34], whereas a biopsychosocial framework of patient education, exercise, and self-management that avoids excessive pharmacological solutions is recommended for CLBP [35–37]. Given the differences in physiopathology, prognosis, and treatment options between spondyloarthritis and CLBP, one could expect that these disorders would have different impacts on HRQoL and different links between the physical, mental, and social domains of HRQoL. Salaffi et al. evaluated HRQoL in different rheumatic disorders [5] and found that patients with inflammatory rheumatic diseases (including spondyloarthritis) had poorer self-reported health in all domains of HRQoL than those without arthritis. However, Kreis et al. found that spondyloarthritis and CLBP similarly affected the physical and mental components of HRQoL [38].

It is important to clarify whether spondyloarthritis and CLBP have different impacts on HRQoL and its domains as their shared symptom—low back pain—may benefit from different pharmacologic and non-pharmacologic interventions depending on the specific factors that impact HRQoL. Moreover, knowledge of the factors associated with HRQoL will allow HRQoL to be promoted in targeted group interventions.

In this population-based study, we assessed and compared the HRQoL of subjects with spondyloarthritis, those with CLBP, and those without rheumatic or musculoskeletal disorders (RMDs). We then investigated the factors associated with HRQoL in spondyloarthritis and CLBP subjects.

Methods

Data source and study population

We collected data from the EpiReumaPt, a large, population-based, observational study conducted from September 2011 to December 2013, to estimate the prevalence of RMDs in Portugal and determine their impact on HRQoL, physical function, and mental health. To obtain a representative sample of the Portuguese population, participants were selected by multistage random sampling. The sampling was stratified in seven regions across the country according to the Nomenclature of Territorial Units for Statistics II (NUTS II): Norte, Centro, Lisboa e Vale do Tejo, Alentejo, Algarve, Região Autónoma dos Açores (the Azores), and Região Autónoma da Madeira (Madeira).

We used a three-stage approach to capture and characterize all cases of RMDs within the adult Portuguese population (Fig. 1). First, interviewers (non-physicians, trained for this purpose) performed face-to-face interviews with a computer-assisted personal interview system at each participant's household. The detailed and comprehensive questionnaire included RMD symptom screening wherein participants were asked about self-reported RMDs and, subsequently, about specific rheumatic and musculoskeletal symptoms. An algorithm was applied to the survey data to screen for specific RMDs. Second, rheumatologists performed a clinical evaluation with a physical examination for all participants identified in the first interview as potentially having an RMD as well as for 20% of the asymptomatic individuals. Finally, three rheumatologists revised the gathered information and defined the final diagnoses. For this analysis, all participants from phase two were included. The study methodology has been described in detail elsewhere [39, 40].

Case definition

Spondyloarthritis diagnosis was established after the second-phase clinical appointment based on expert opinion (in total, 95 rheumatologists were involved) and fulfillment of validated classification criteria [22, 23]. Subtypes, such as ankylosing spondylitis, psoriatic arthritis, and other spondyloarthritis, were defined by expert opinion. CLBP was self-reported and defined as pain between the lower margin of the twelfth ribs and the lower gluteal folds (with or without pain referred to the lower limbs) that was present on the

day of the interview and experienced most of the time for the previous 90 days. The population without RMDs was also identified by expert opinion after clinical history and physical examination.

Variables


Sociodemographic data were collected for all groups, including age, gender (male, female), ethnicity (caucasian, other), marital status (married, other), and education level (0–4, 5–9, 10–12 years, > 12 years). Lifestyle habits were also queried, including alcohol intake (daily, occasional, never), daily coffee intake (none, 1–3 cups, > 3 cups), smoking habits (daily, occasionally, never), and regular physical exercise (defined as physical activity > 1 h/week; yes, no). Employment status (full-time active worker, part-time active worker, domestic worker, unemployed, retired, student, temporary work disability, other) was also registered.

Anthropometric data were collected (weight [kg], height [cm], body mass index [BMI; kg/m²]), as were self-reported noncommunicable chronic diseases, including high cholesterol, high blood pressure, allergies, gastrointestinal disease, mental disorders, cardiac disease, diabetes, thyroid and parathyroid disease, renal disease, pulmonary disease, hyperuricemia, cancer, neurologic disease, and hypogonadism.

HRQoL data were collected using the EQ-5D, 3-level, Portuguese version (hereafter EQ-5D) [41]. The EQ-5D comprises a health descriptive component and a visual analog scale (VAS). The descriptive component evaluates five dimensions, each describing a different aspect of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three levels: no problems, some problems, and extreme problems (labeled 1–3, respectively) [41, 42]. For the analyses, we aggregated the “some problems” and “extreme problems” levels, thus considering only two levels in each domain. Scores from the three items can be used to derive a single utility score. The descriptive system was converted into a summary index score ranging from –1 (states worse than death, with 0 equivalent to death) to 1 (full health) [43]. The VAS is a 20-cm vertical scale of 0–100 points, where, similarly, scores of 0 and 100 correspond to the “worst imaginable health state” and the “best imaginable health state,” respectively [42]. Subjects with CLBP recorded pain intensity on the interview day using a numeric rating scale of 0–10, and question 2 of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to evaluate back pain intensity in spondyloarthritis.

In the clinical appointment in the second-phase of the EpiReumaPt study, spondyloarthritis subjects were evaluated with disease-specific assessments, including the Ankylosing Spondylitis Disease Activity Score (ASDAS), BASDAI, Bath Ankylosing Spondylitis Functional Index

Fig. 1 Flowchart of recruitment in the EpiReumaPt study. RMD, rheumatic and musculoskeletal disorders; CLBP, chronic low back pain



(BASFI), and patient's global assessment of the disease in the last week (PtGA), registered on a VAS (0–100 mm). Furthermore, a blood sample was drawn to measure C-reactive protein (CRP; mg/l). A physician's global assessment of the disease (PhGA) was also registered (VAS, 0–100 mm). In spondyloarthritis, remission/inactive disease was defined according to the predominant phenotype: ASDAS ≤ 1.3 defined inactive axial spondyloarthritis, and PhGA ≤ 20 mm was used for other forms of spondyloarthritis.

Statistical methods

Descriptive data for each categorical variable is presented as the absolute frequency and the corresponding proportion. Mean and standard deviation (SD) are shown for each continuous variable.

Subjects with spondyloarthritis were compared with subjects with CLBP and subjects without RMDs, and CLBP patients were also compared with subjects without RMDs. Comparisons were made using the Chi-square test and

Fisher's exact test for categorical variables and the independent t-test for continuous variables. To assess HRQoL differences (measured by EQ-5D) between the three groups, univariable and multivariable linear regression analyses were used for continuous outcomes and univariable or multivariable logistic regression analyses were used for binary outcomes. According to the results of the univariable analyses, the following confounders were included: for comparison between spondyloarthritis and CLBP subjects—gender, age group, NUTS II region, education level, employment status, BMI, and number of noncommunicable chronic diseases; for comparison between spondyloarthritis subjects and those without RMDs—gender, age group, NUTS II region, education level, marital status, and noncommunicable chronic diseases; for comparison between CLBP subjects and those without RMDs—gender, age group, NUTS II region, education level, employment status, marital status, BMI, regular physical exercise, and number of noncommunicable chronic diseases.

To assess the determinants of HRQoL (evaluated by EQ-5D) in subjects with spondyloarthritis, univariable linear regression was first performed to select the variables to include in the final model, considering a significance level of 0.2 to avoid an early exclusion of potentially important variables. The individual variables tested were: gender, age group (18–35, 36–55, 56–75 years, ≥ 76 years), education level (0–4, 5–9, 10–12 years, > 12 years), NUTS II region (Norte, Centro, Lisboa, Alentejo, Algarve, Azores, Madeira), marital status (married, other), employment status (active worker [full and part-time], unemployed, retired, other [domestic, student, temporary work disability]), BMI (normal, overweight, obese), daily coffee intake (none, 1–3 cups, > 3 cups), alcohol intake (daily, occasionally, never), smoking habits (smoker, non-smoker), regular physical exercise (yes, no), number of noncommunicable diseases (0–2, ≥ 3), and disease activity (active, inactive). After selecting the variables to include in the multivariable model, we sequentially excluded non-statistically significant variables through a backward conditional method and compared the models through ANOVA.

We followed the same methodology to assess determinants of HRQoL in subjects with CLBP. The independent variables tested were the same, except for disease activity, which was replaced by low back pain intensity (0–10).

The significance level was set at 0.05. All analyses were performed using Stata/IC (v.16.1).

Ethical framework

EpiReumaPt was performed according to the principles established by the Declaration of Helsinki. The study was reviewed and approved by the National Committee for Data Protection and the NOVA Medical School Ethics

Committee. Participants signed informed consent documents before participation [39].

Results

The analyses included 92 subjects with spondyloarthritis, 1376 with CLBP, and 679 without RMDs. Of the 92 subjects with spondyloarthritis, 32 had ankylosing spondylitis, 20 had psoriatic arthritis, and 40 had other forms of spondyloarthritis.

Spondyloarthritis subjects had a mean PtGA of 5.2 ± 2.7 , PhGA of 3.8 ± 2.2 , global spine pain (in the last 48 h) of 4.6 ± 2.8 , BASDAI score of 5.9 ± 3.1 , ASDAS-CRP of 2.6 ± 1.0 and BASFI score of 4.8 ± 3.6 . The mean low back pain intensity in subjects with CLBP was 5.5 ± 2.2 .

Sociodemographic, lifestyle, and health characteristics of subjects with spondyloarthritis, CLBP, or no RMDs

The mean age was 48.4 ± 13.7 years for spondyloarthritis subjects, 58.8 ± 14.6 years for CLBP subjects, and 45.9 ± 15.6 years for subjects without RMDs. All three groups had a female predominance (64.1%, 70.3%, and 53.9%, respectively). Anthropometric data and sociodemographic, lifestyle, and health characteristics of the three groups are summarized in Tables 1 and 2.

Compared with spondyloarthritis subjects, CLBP subjects were older and had a lower level of education, a higher proportion of retired individuals (Table 1), more overweight or obese individuals, and a higher number of self-reported noncommunicable diseases, namely high blood pressure, diabetes, and high cholesterol (Table 2). They also had a lower coffee intake than subjects with spondyloarthritis. However, there were no differences in alcohol consumption, smoking habits, or regular physical exercise between these two groups (Table 2).

Sociodemographic and lifestyle characteristics were similar between spondyloarthritis subjects and those without RMDs, except for marital status, as the former had a higher proportion of married individuals; regarding noncommunicable chronic diseases (self-reported), spondyloarthritis patients had higher proportions of pulmonary, gastrointestinal, renal, and thyroid diseases (Tables 1 and 2).

HRQoL in subjects with spondyloarthritis, CLBP, or no RMDs

Spondyloarthritis subjects had much lower HRQoL than subjects without RMDs, reflected by the EQ-5D index score (0.69 ± 0.25 and 0.86 ± 0.21 , respectively; $\beta = -0.14$, 95% CI $[-0.19; -0.10]$; $p < 0.001$). The same was found

Table 1 Sociodemographic characteristics of participants with spondyloarthritis, those with chronic low back pain, and those without rheumatic or musculoskeletal disorders

	Spondyloarthritis <i>n</i> = 92	CLBP <i>n</i> = 1376	noRMD <i>n</i> = 679	<i>p</i> -value (SpA/noRMD)	<i>p</i> -value (CLBP/noRMD)	<i>p</i> -value (SpA/CLBP)
Female	59 (64.13%)	965 (70.13%)	366 (53.90%)	0.074 ^a	<< 0.001^a	0.241 ^a
Age (mean ± SD)	48.4 ± 13.7	58.8 ± 14.6	45.9 ± 15.6	0.145 ^b	<< 0.001^b	<< 0.001^b
Age group				0.546 ^c	<< 0.001^c	<< 0.001^c
18–35 years	19 (20.65%)	88 (6.4%)	187 (27.54%)			
36–55 years	47 (51.09%)	446 (32.41%)	311 (45.80%)			
56–75 years	23 (25.00%)	654 (47.53%)	159 (23.42%)			
≥ 76 years	3 (3.26%)	188 (13.66%)	22 (3.24%)			
Education level				0.709 ^c	<< 0.001^c	<< 0.001^c
0–4 years	32 (34.78%)	811 (59.24%)	207 (30.53%)			
5–9 years	22 (23.91%)	275 (11.69%)	138 (20.35%)			
10–12 years	20 (21.74%)	160 (20.09%)	179 (26.40%)			
> 12 years	18 (19.57%)	123 (8.98%)	154 (22.71%)			
NUTS II region				0.075 ^c	<< 0.001^c	0.085 ^c
Norte	21 (22.83%)	425 (30.89%)	196 (28.87%)			
Centro	27 (29.35%)	349 (25.36%)	122 (17.97%)			
Lisboa	12 (13.04%)	232 (16.86%)	122 (17.97%)			
Alentejo	7 (7.60%)	92 (6.69%)	39 (5.74%)			
Algarve	6 (6.52%)	25 (1.82%)	27 (3.98%)			
Azores	11 (11.96%)	140 (10.17%)	74 (10.90%)			
Madeira	8 (8.70%)	113 (8.21%)	99 (14.58%)			
Marital status				0.043^a	0.001^a	0.500 ^a
Married	63 (68.48%)	890 (64.68%)	388 (57.31%)			
Other	29 (31.52%)	486 (35.32%)	289 (42.69%)			
Employment status				0.406 ^c	<< 0.001^c	<< 0.001^c
Full-time worker	48 (52.75%)	400 (29.52%)	352 (52.93%)			
Unemployed	14 (15.38%)	132 (9.74%)	93 (13.98%)			
Retired	23 (25.27%)	649 (47.90%)	142 (21.35%)			
Other	6 (6.59%)	174 (12.84%)	78 (11.73%)			

Bold indicates statistically significant results (significance level set at 0.05)

^aFisher's exact test

^bt-test

^cChi-square test

SD Standard deviation, SpA Spondyloarthritis, CLBP Chronic low back pain, noRMD Without rheumatic or musculoskeletal disorders, NUTS II Nomenclature of Territorial Units for Statistics II.

when comparing CLBP subjects and those without RMDs (0.66 ± 0.27 and 0.86 ± 0.2 , respectively; $\beta = -0.12$, 95% CI $[-0.14; -0.09]$; $p < 0.001$) (Table 3).

Spondyloarthritis and CLBP subjects had similar HRQoL (0.69 ± 0.25 and 0.66 ± 0.27 , respectively; $\beta = -0.03$, 95% CI $[-0.08; 0.03]$; $p = 0.33$). Subjects with spondyloarthritis and CLBP reported problems in all EQ-5D dimensions in similar proportions but to a much greater extent than subjects without RMDs. Almost 60% of spondyloarthritis subjects reported pain (moderate or extreme), and approximately one-third reported some or extreme problems with

mobility and usual activities. Some or extreme problems with self-care were also more common in spondyloarthritis and CLBP subjects compared with subjects without RMDs.

Spondyloarthritis subjects showed a lower individual perception of health, measured by EQ-5D VAS (higher scores correspond to better health) than subjects without RMDs (65.28 ± 18.1 and 75.69 ± 17.64 , respectively; $\beta = -7.49$, 95% CI $[-11.2; -3.78]$; $p < 0.001$), and the same relationship was found for CLBP subjects and those without RMDs (60.92 ± 19.86 and 75.69 ± 17.64 , respectively; $\beta = -9.07$, 95% CI $[-10.96; -7.18]$; $p < 0.001$) (Table 3). After we

Table 2 Anthropometric data and lifestyle and health characteristics among participants with spondyloarthritis, those with chronic low back pain, and those without rheumatic or musculoskeletal disorders

	Spondyloarthritis <i>n</i> = 92	CLBP <i>n</i> = 1376	noRMD <i>n</i> = 679	<i>p</i> -value (SpA/noRMD)	<i>p</i> -value (CLBP/noRMD)	<i>p</i> -value (SpA/CLBP)
<i>BMI (kg/m²)</i>				0.585 ^a	<< 0.001^a	0.003^a
Normal	41 (46.07%)	372 (29.11%)	315 (47.51%)			
Overweight	32 (35.96%)	527 (41.24%)	255 (38.46%)			
Obese	16 (17.98%)	379 (29.66%)	93 (14.03%)			
<i>Daily coffee intake (cups)</i>				0.141 ^a	<< 0.001^a	<< 0.001^a
None	23 (25%)	512 (37.21%)	179 (26.36%)			
1–3	53 (57.61%)	785 (57.05%)	429 (63.18%)			
> 3	16 (17.39%)	79 (5.74%)	71 (10.46%)			
<i>Alcohol intake</i>				0.194 ^a	<< 0.001^a	0.959 ^a
Daily	20 (21.74%)	285 (20.73%)	132 (19.44%)			
Occasionally	30 (32.61%)	426 (30.98%)	288 (42.41%)			
Never	42 (45.65%)	664 (48.29%)	259 (38.14%)			
<i>Smoking habits</i>				0.468 ^a	<< 0.001^a	0.339 ^a
Daily	14 (15.22%)	160 (11.63%)	140 (20.62%)			
Occasionally	2 (2.17%)	20 (1.45%)	16 (2.36%)			
Non-smoker	76 (82.61%)	1196 (86.92%)	523 (77.03%)			
<i>Regular physical exercise</i>				0.165 ^b	<< 0.001^b	0.812 ^b
Yes	27 (29.35%)	388 (28.20%)	253 (37.32%)			
No	65 (70.65%)	988 (71.80%)	425 (62.68%)			
<i>Chronic noncommunicable diseases, n (self-reported)</i>				<< 0.001^b	<< 0.001^b	0.048^b
0–2	51 (55.43%)	617 (44.84%)	517 (76.37%)			
≥ 3	41 (44.57%)	759 (55.16%)	160 (23.63%)			
<i>Chronic noncommunicable diseases (self-reported)</i>						
High blood pressure	20 (21.74%)	610 (44.65%)	158 (23.51%)	0.793 ^b	<< 0.001^b	<< 0.001^b
Diabetes	4 (4.35%)	211 (15.45%)	63 (9.36%)	0.165 ^b	<< 0.001^b	0.002^b
High cholesterol	31 (34.07%)	615 (45.52%)	181 (27.05%)	0.171 ^b	<< 0.001^b	0.038^b
Pulmonary disease	11 (11.96%)	116 (8.49%)	41 (6.07%)	0.045^b	0.063 ^b	0.251 ^b
Cardiac disease	11 (12.09%)	267 (19.62%)	56 (8.33%)	0.237 ^b	<< 0.001^b	0.097 ^b
Gastrointestinal	23 (25.56%)	407 (29.86%)	78 (11.61%)	0.001^b	<< 0.001^b	0.474 ^b
Neurological	1 (1.09%)	64 (4.69%)	22 (3.27%)	0.344 ^b	0.159 ^b	0.121 ^b
Allergy	23 (25.00%)	364 (26.67%)	145 (21.61%)	0.502 ^b	0.014^b	0.808 ^b
Mental	14 (15.38%)	332 (19.62%)	71 (10.52%)	0.159 ^b	<< 0.001^b	0.056 ^b
Cancer	3 (3.26%)	67 (4.91%)	36 (5.33%)	0.611 ^b	0.669 ^b	0.619 ^b
Thyroid	14 (15.22%)	193 (14.26%)	51 (7.55%)	0.025^b	<< 0.001^b	0.759 ^b
Hypogonadism	1 (1.11%)	13 (0.97%)	7 (1.04%)	0.953 ^b	0.878 ^b	0.599 ^b
Hyperuricemia	5 (5.43%)	137 (10.18%)	24 (3.60%)	0.382 ^b	<< 0.001^b	0.203 ^b
Renal	11 (12.09%)	167 (12.31%)	38 (5.66%)	0.036^b	<< 0.001^b	0.951 ^b

Bold indicates statistically significant results (significance level set at 0.05)

^aChi-square test

^bFisher's exact test

SpA Spondyloarthritis, CLBP Chronic low back pain, noRMD Without rheumatic or musculoskeletal disorders, BMI Body mass index.

adjusted for confounders, spondyloarthritis and CLBP subjects showed similar individual perceptions of health (65.28 ± 18.1 and 60.92 ± 19.86 , respectively; $\beta = 0.20$, 95% CI $[-3.88; 4.27]$; $p = 0.925$).

Determinants of HRQoL in spondyloarthritis

After univariable linear regression analysis (Supplementary Table 1) we performed a multivariable model

Table 3 Comparison of health-related quality of life by diagnosis (spondyloarthritis, chronic low back pain, or no rheumatic/musculoskeletal disorders)

	SpA <i>n</i> = 92	CLBP <i>n</i> = 1376	noRMD <i>n</i> = 679	Crude OR SpA/noRMD [95% CI]	Crude <i>p</i> -value SpA/ noRMD	Adjusted SpA/noRMD ^a [95% CI]	Adjusted <i>p</i> -value SpA/ noRMD ^a	Crude OR CLBP/noRMD [95% CI]	Crude <i>p</i> -value CLBP/ noRMD	Adjusted CLBP/noRMD ^b [95% CI]	Adjusted <i>p</i> -value CLBP/ noRMD ^b	Crude OR SpA/ CLBP [95% CI]	Crude <i>p</i> -value SpA/ CLBP	Adjusted OR SpA/ CLBP ^c [95% CI]	Adjusted <i>p</i> -value SpA/ CLBP ^c
EQ-5D															
Mobility				4.34 [2.59; 7.18]	< 0.001	4.54 [2.50; 8.21]	< 0.001	5.86 [4.47; 7.79]	< 0.001	3.11 [2.28; 4.31]	< 0.001	0.74 [0.47; 1.16]	0.196	1.37 [0.81; 2.28]	0.229
No problems, <i>n</i> (%)	63 (68.5)	849 (61.7)	613 (90.4)												
Some problems/ extreme problems, <i>n</i> (%)	29 (31.5)	527 (38.3)	65 (9.6)												
Self-care				4.23 [1.83; 9.23]	< 0.001	4.86 [1.85; 12.6]	0.001	6.54 [4.16; 10.90]	< 0.001	3.21 [1.90; 5.78]	< 0.001	0.65 [0.31; 1.21]	0.204	1.37 [0.63; 2.76]	0.397
No problems, <i>n</i> (%)	82 (89.1)	1156 (84.1)	659 (97.2)												
Some problems/ Extreme problems, <i>n</i> (%)	10 (10.8)	218 (15.9)	19 (2.8)												
Usual activi- ties				4.42 [2.64; 7.34]	< 0.001	4.65 [2.56; 8.44]	< 0.001	4.62 [3.51; 6.17]	< 0.001	2.50 [1.83; 3.47]	< 0.001	0.96 [0.60; 1.49]	0.849	1.59 [0.94; 2.64]	0.075
No problems, <i>n</i> (%)	63 (68.5)	927 (67.5)	615 (90.6)												
Some prob- lems/ extreme problems, <i>n</i> (%)	29 (31.5)	446 (32.5)	64 (9.4)												
Pain/discom- fort				5.15 [3.28; 8.20]	< 0.001	4.73 [2.94; 7.70]	< 0.001	4.80 [3.91; 5.92]	< 0.001	3.46 [2.75; 4.37]	< 0.001	1.07 [0.70; 1.67]	0.748	1.35 [0.85; 2.19]	0.213
No pain or discomfort, <i>n</i> (%)	35 (38.0)	546 (39.7)	516 (76.0)												
Moderate/ extreme pain or discomfort, <i>n</i> (%)	57 (62.0)	828 (60.3)	163 (24.0)												

Table 3 (continued)

	SpA <i>n</i> = 92	CLBP <i>n</i> = 1376	noRMD <i>n</i> = 679	Crude OR SpA/noRMD [95% CI]	Crude <i>p</i> -value SpA/ noRMD	Adjusted OR SpA/noRMD ^a [95% CI]	Adjusted <i>p</i> -value SpA/ noRMD ^a	Crude OR CLBP/noRMD [95% CI]	Crude <i>p</i> -value CLBP/ noRMD	Adjusted OR CLBP/noRMD ^b [95% CI]	Adjusted <i>p</i> -value CLBP/ noRMD ^b	Crude OR CLBP [95% CI]	Crude <i>p</i> -value SpA/ CLBP	Adjusted OR SpA/ CLBP ^c [95% CI]	Adjusted <i>p</i> -value SpA/ CLBP ^c
Anxiety/ depression				1.961 [1.18; 3.17]	0.007 1.50 [0.87; 2.49]	0.135 2.02 [1.61; 2.54]	< 0.001 1.58 [1.21; 2.07]	0.908	0.97 [0.60; 1.53]	0.001 0.03 [−0.03; 0.09]	< 0.001 0.03 [−0.03; 0.03]	0.14 [0.68; 1.88]	0.908	1.14 [0.68; 1.88]	0.604
Not anxious or depressed, <i>n</i> (%)	65 (70.7)	958 (70.1)	557 (82.5)												
Moderately/ extremely anxious or depressed, <i>n</i> (%)	27 (29.4)	409 (29.9)	118 (17.5)												
EQ-5D score (mean ± SD)	0.69 ± 0.25	0.66 ± 0.27	0.86 ± 0.21	−0.17 [−0.21; −0.12]	< 0.001 −0.14 [−0.19; −0.10]	< 0.001 −0.20 [−0.22; −0.174]	< 0.001 −0.12 [−0.14; −0.09]	0.300	0.03 [−0.03; 0.09]	< 0.001 0.03 [−0.03; 0.03]	< 0.001 0.03 [−0.03; 0.03]	0.33	0.300	−0.03 [−0.08; 0.03]	0.33
EQ-5D VAS (mean ± SD)	65.28 ± 18.1	60.92 ± 19.86	75.69 ± 17.64	−10.41 [−14.34; 6.49]	< 0.001 −7.49 [−11.20; −3.78]	< 0.001 −14.77 [−16.57; −12.97]	< 0.001 −9.07 [−10.96; −7.18]	0.040	0.03 [−4.06; 4.12]	< 0.001 4.36 [0.11; 8.60]	< 0.001 4.36 [0.11; 8.60]	0.03 [−4.06; 4.12]	0.040	0.03 [−4.06; 4.12]	0.989

Bold indicates statistically significant results (significance level set at 0.05)

EQ-5D, EuroQoL 5 dimensions; EQ-5D-VAS, EQ-5D Visual Analogue Scale; SpA, Spondyloarthritis; CLBP, Chronic low back pain; noRMD, Without rheumatic or musculoskeletal diseases; SD, Standard deviation; CI, Confidence interval; OR, Odds ratio; ^aOR adjusted for: gender, age group, NUTS II region, marital status, number of noncommunicable diseases; ^bOR adjusted for: gender, age group, NUTS II region, education level, employment status, marital status, body mass index category, regular physical exercise, number of noncommunicable diseases; ^cOR adjusted for: gender, age group, NUTS II region, education level, employment status, body mass index category, number of noncommunicable diseases.

Table 4 Factors associated with health-related quality of life (EQ-5D), stratified by diagnostic category (multivariable model)

	Chronic low back pain <i>n</i> = 1376			Spondyloarthritis <i>n</i> = 92		
	β	95% CI	<i>p</i> -value	β	95% CI	<i>p</i> -value
<i>Age</i>						
18–35 years	1					
≥ 76 years	− 0.09	[− 0.17; − 0.01]	0.022	–	–	–
<i>NUTS II region</i>				–	–	–
Lisbon	1					
North	0.03	[− 0.01; 0.07]	0.158			
Center	0.03	[− 0.01; 0.07]	0.132			
Alentejo	0.08	[0.01; 0.14]	0.020			
Algarve	0.17	[0.05; 0.28]	0.004			
Azores	0.01	[− 0.04; 0.06]	0.667			
Madeira	0.03	[− 0.03; 0.08]	0.350			
<i>Marital status</i>						
Married	1					
Non-married	− 0.03	[− 0.06; − 0.005]	0.024	–	–	–
<i>Employment status</i>				–	–	–
Full-time work	1					
Retired	− 0.07	[− 0.12; − 0.03]	< 0.001			
Other	− 0.06	[− 0.11; − 0.02]	0.007			
<i>Weight</i>						
Normal	1					
Obese (BMI ≥ 30 kg/m ²)	− 0.04	[− 0.08; − 0.01]	0.022	–	–	–
<i>Alcohol intake</i>						
Never	1					
Daily	0.07	[0.03; 0.10]	< 0.001	–	–	–
<i>Regular physical exercise</i>						
No	1					
Yes	0.08	[0.05; 0.11]	< 0.001	0.18	[0.10; 0.30]	< 0.001
<i>Number of comorbidities</i>						
0–2	1					
≥ 3	− 0.11	[− 0.14; − 0.08]	< 0.001	− 0.18	[− 0.24; − 0.03]	< 0.001
<i>Disease activity (BASDAI)</i>						
Inactive	1					
Active	–	–	–	− 0.13	[− 0.29; − 0.05]	0.036
Low back intensity (0–10)	− 0.02	[− 0.03; − 0.02]	< 0.001	–	–	–
	<i>R</i> ² = 0.214			<i>R</i> ² = 0.329		

Bold indicates statistically significant results (significance level set at 0.05)

EQ-5D, European Quality of Life Questionnaire Five Dimensions; NUTS II, Nomenclature of Territorial Units for Statistics II; BMI, Body mass index; β , Parameter estimates; CI, Confidence interval; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index.

to assess determinants of HRQoL in subjects with spondyloarthritis (Table 4). Having three or more comorbidities was negatively associated with HRQoL ($\beta = -0.18$, 95% CI [− 0.24; 0.03]; $p < 0.001$). Specifically, patients with multimorbidity (≥ 3 noncommunicable diseases) had a mean EQ-5D score reduced by 0.18 points compared with patients with up to two noncommunicable diseases, holding all the other variables constant. Moreover,

subjects with active disease also showed a worse HRQoL ($\beta = -0.13$, 95% CI [− 0.29; − 0.05]; $p = 0.036$), with a mean EQ-5D score reduced by 0.13 points compared with patients with inactive disease, holding all the other variables constant. Regular physical exercise was significantly associated with better HRQoL ($\beta = 0.18$, 95% CI [0.10; 0.30]; $p < 0.001$), and patients who performed regular physical activity had a mean EQ-5D score increased by

0.18 points compared with patients who did not, holding all the other variables constant.

Determinants of HRQoL in CLBP

After univariable linear regression analysis (Supplementary Table 1) we performed a multivariable model to assess determinants of HRQoL in subjects with CLBP (Table 4). Several variables were significantly associated with HRQoL. Age ≥ 76 years ($\beta = -0.09$; 95% CI $[-0.17; -0.01]$; $p=0.022$), non-married marital status ($\beta = -0.03$; 95% CI $[-0.06; -0.005]$; $p=0.024$), retirement ($\beta = -0.07$; 95% CI $[-0.12; -0.03]$; $p<0.001$) or other employment status ($\beta = -0.06$; 95% CI $[-0.11; -0.02]$; $p=0.007$), obesity ($\beta = -0.04$; 95% CI $[-0.08; -0.01]$; $p=0.022$), multimorbidity ($\beta = -0.11$; 95% CI $[-0.14; -0.08]$; $p<0.001$), and low back pain intensity ($\beta = -0.02$; 95% CI $[-0.03; -0.02]$; $p<0.001$) were significantly associated with worse HRQoL in CLBP subjects. Patients who were 76 years old or more had a mean EQ-5D score reduced by 0.09 points compared with 18–35-year-old patients; non-married patients had a mean EQ-5D score reduced by 0.03 points compared with married patients; retired patients and patients with other work statuses (domestic worker, student, temporary work disability) had mean EQ-5D scores reduced by 0.07 and 0.06 points, respectively, compared with full-time workers, holding all the other variables constant; obese patients had a mean EQ-5D score reduced by 0.04 points compared with normal-weight patients; patients with multimorbidity had a mean EQ-5D score reduced by 0.11 points compared with patients with up to two noncommunicable diseases; and for each centimeter increase in low back pain VAS, the mean EQ-5D score was reduced by 0.02 points, holding all the other variables constant. By contrast, patients from Alentejo ($\beta=0.08$; 95% CI $[0.01; 0.14]$; $p=0.020$), or Algarve ($\beta=0.17$; 95% CI $[0.05; 0.28]$; $p=0.004$) and those with daily alcohol intake ($\beta=0.07$; 95% CI $[0.03; 0.10]$; $p<0.001$) and regular physical exercise ($\beta=0.08$; 95% CI $[0.05; 0.11]$; $p<0.001$) had better HRQoL. Patients living in Alentejo or Algarve had EQ-5D scores increased by 0.08 and 0.17 points, respectively, compared with Lisbon residents. Daily alcohol intake was associated with an EQ-5D increase of 0.07 points compared with patients who did not drink alcohol, holding all the other variables constant. Moreover, regular physical exercise was significantly associated with better HRQoL, with a 0.08 increase in the mean EQ-5D score compared with patients who did not exercise regularly, holding all the other variables constant.

Discussion

HRQoL in subjects with spondyloarthritis, CLBP, or no RMDs

Our study showed that spondyloarthritis and CLBP patients had a significantly decreased HRQoL compared with the population without RMDs. We used EQ-5D to assess HRQoL because it is one of the most commonly used generic instruments for this purpose in general population surveys and has been used in several RMD surveys [5, 9, 44]. Moreover, the validity and reliability of EQ-5D have been proven for spondyloarthritis [45–47] and CLBP [48–50].

Previous studies have also reported poorer HRQoL in spondyloarthritis patients compared with the general population [27, 51, 52]. In this study, spondyloarthritis patients showed worse HRQoL in all domains compared with adults without RMDs. However, after adjustment for confounders, anxiety/depression was no longer significantly different. Sixty-two percent of our patients reported moderate or extreme pain/discomfort, and 31.5% reported problems with mobility and usual activities, suggesting that there is inadequate disease control and significant disease burden despite the several different treatment approaches available to these patients [33, 34]. Our findings regarding the impact on HRQoL are in line with a recent meta-analysis by Yang et al., who analyzed 38 studies on HRQoL in ankylosing spondylitis. These authors included studies that evaluated HRQoL by the Short-Form-36 questionnaire (SF-36) and concluded that the disease significantly impaired all SF-36 dimensions, although physical health was more likely to be affected than mental health [25].

Our results showed that HRQoL was globally impaired in CLBP compared with an adult population without RMDs. Previous cross-sectional and prospective studies also showed lower HRQoL in CLBP, with a significant negative impact on both the physical and mental domains [16–20]. In our study, more than half of the patients reported moderate to extreme pain/discomfort and 38% reported mobility limitations; however, even less-affected domains (e.g., self-care) showed a significant difference from the population without RMDs. These findings suggest that particular attention should be given to pain control in CLBP patients to improve HRQoL. The need for a biopsychosocial approach to CLBP, with patient education, exercise, and self-management [35–37], has been universally accepted; however, this approach may undervalue pain control—a major driver of HRQoL—resulting in a higher disease burden. Eusébio et al. [53] concluded that intake of analgesics and other pain relief drugs was very low among 1487 patients with active CLBP, even for those who reported severe pain, confirming the insufficient pain control in these patients.

Direct comparison of HRQoL in spondyloarthritis with that in other rheumatic conditions is scarce and has focused mainly on rheumatoid arthritis, where substantial differences do not seem to exist [27, 51, 54–56]. In our study, spondyloarthritis and CLBP showed similar impacts on HRQoL. We found no differences in the physical, emotional, and social HRQoL domains between spondyloarthritis and CLBP despite different physiopathology, prognosis, and treatment options. Because low back pain is the leading cause of years lived with disability in most countries [3], these results are perhaps not unexpected. However, HRQoL has rarely been compared among spondyloarthritis patients, and this is the first study to make a direct comparison between spondyloarthritis and CLBP at a population level. Kreis et al. [38] used the Short-Form 12 survey to compare HRQoL in 199 axial spondyloarthritis and 89 CLBP patients, finding similar HRQoL for both diseases. This aligns with our results, as the EQ-5D index scores we obtained for spondyloarthritis and CLBP were not significantly different between conditions. Still, the scores were significantly lower than those of the adult Portuguese population without RMDs, confirming poorer HRQoL in both diseases [43].

Individual perception of health, assessed by EQ-5D VAS, is a much broader concept including both rheumatic problems and the general state of health. In our study, individuals with spondyloarthritis showed a worse perception of health than the population without RMDs, likely related to their rheumatic condition as we found no significant differences in the other variables. CLBP patients also showed worse perceptions of health than the population without RMDs; however, in this group, factors other than the rheumatic condition—e.g., older age, a higher proportion of retired subjects, a higher prevalence of overweight/obesity, and more self-reported chronic noncommunicable diseases like high blood pressure, diabetes, and high cholesterol—could have substantially influenced health perception. Spondyloarthritis and CLBP patients did not show significant differences in individual perceptions of health. Hence, these two chronic disorders are associated with a significantly low individual perception of health independent of the different physiopathology, prognosis, and treatment options.

Determinants of HRQoL in spondyloarthritis

This study also identified determinants of HRQoL. We found that higher disease activity was an independent factor associated with HRQoL among spondyloarthritis patients. Previous studies have also found disease activity to be an independent determinant of HRQoL in early and advanced forms of axial spondyloarthritis [28, 57, 58]. This finding is clinically relevant as it suggests that strict control of disease activity is crucial to achieving better HRQoL in spondyloarthritis patients. Furthermore, we found that multimorbidity

was associated with worse HRQoL in spondyloarthritis patients. Fitzgerald et al. [59] found a similar association between multimorbidity and worse HRQoL, evaluated by a disease-specific instrument (Ankylosing Spondylitis Quality of Life questionnaire), in the Ireland national registry, although they defined multimorbidity as the presence of two or more chronic noncommunicable diseases. There has been a growing interest in the prevalence and impact of comorbidities in spondyloarthritis in recent years. Several studies have found a higher prevalence of comorbidities, specifically cardiovascular and metabolic disorders [59, 60], in spondyloarthritis patients than in the general population, which was reinforced in a recent meta-analysis that identified a higher prevalence of hypertension, dyslipidemia, and obesity in axial spondyloarthritis patients [61]. Our results emphasize the importance of addressing multimorbidity to minimize its impact on HRQoL.

Regular physical exercise was strongly associated with better HRQoL in spondyloarthritis. Even considering that regular exercise was self-reported and prone to recall and reporting bias, this result likely reflects the positive effect of exercise on overall well-being (not only in specific aspects of HRQoL, such as function) and emphasizes the benefit of exercise in different health dimensions. Although patients with lower disease activity may have better HRQoL and be able to exercise more regularly due to experiencing less pain, these two factors were independently associated with HRQoL in our study. Nevertheless, the cross-sectional design of our study does not allow us to infer a causal effect of the benefit of regular exercise on HRQoL, and a follow-up study of this cohort would be valuable. Exercise as a recreational activity is less well studied in spondyloarthritis than physical therapy or therapeutic exercise, and previous work has mainly addressed the effect of exercise on physical function, specifically associating exercise with improved function [62, 63].

Determinants of HRQoL in CLBP

Our results show that being female was negatively associated with HRQoL, in line with previous studies showing that HRQoL was lower in female subjects than in male subjects with CLBP [64, 65]. However, other authors did not find any association between HRQoL and gender in this population [66–69]. Age has been linked to HRQoL in other cohorts with contradictory results. As in our study, some research [64, 66, 70] has found that older age was associated with a worse HRQoL, but other authors have come to different conclusions [65, 71]. For example, Wettstein et al. evaluated 228 patients with CLBP and found that HRQoL was the same or higher in older patients compared with younger patients and that increasing age was mainly associated with disability [71]. Most other studies [17, 66, 69, 71–73] have shown

that low back pain intensity negatively influenced HRQoL, and this finding is corroborated by our results; by contrast, Aminde et al. did not find any association between low back pain intensity and HRQoL [67]. We found an association between not being married and worse HRQoL, confirming data from the literature [20, 65]. Uchmanowicz et al. [65] similarly found that single, divorced, or widowed people had worse HRQoL than people who were married or in a relationship, with the social domain being the most affected. The same authors also showed improvements in the social domain of HRQoL for professionally active individuals compared with unemployed people. In our study, retirement and other employment statuses (including domestic workers, students, and those with a temporary work disability) were also associated with a worse HRQoL.

As in the spondyloarthritis subjects, we found an association between worse HRQoL and multimorbidity in people with CLBP. Comorbidities are being increasingly recognized as an important aspect of patients' conditions as they influence several disease outcomes, including HRQoL [59, 61, 74, 75]. We found an association between obesity and worse HRQoL in CLBP patients. It is well-known that the population incidence of CLBP is directly associated with BMI [76] and that overweight and obesity are risk factors for CLBP [77]; moreover, obesity impairs HRQoL [78], and higher degrees of obesity are associated with greater impairment [79]. Our results were therefore somewhat expected, but they have not been previously reported. The positive association of two NUTS II regions (Alentejo and Algarve) with HRQoL is intriguing because no regional differences in HRQoL were found in the EpiDoc cohort [6]. Other authors have reported a better HRQoL in people living in cities compared with those living in villages or small towns, contradicting our results [65]. Also intriguing is the positive association between daily alcohol intake and HRQoL as alcohol consumption is usually associated with worse HRQoL [80]. This might suggest that a small daily consumption is associated with a more positive psychological profile, but this is purely speculative. Finally, as in the spondyloarthritis subjects, regular physical exercise was positively associated with better HRQoL in CLBP. Several studies have addressed the effects of exercise in CLBP patients, but their results are considerably heterogeneous and mainly focus on pain, for which exercise seems beneficial [81]. In line with our findings, Schaller et al. [82] reported that patients achieving the World Health Organization recommendation for leisure time physical activities (≥ 600 metabolic equivalent of task minutes/week) had a better HRQoL than those reporting no such activities. As previously mentioned, patients with lower pain intensity may be able to exercise more regularly, so only a future longitudinal study that follows up with these patients will be able to confirm our findings on the benefits of exercise for HRQoL.

Strengths and limitations

Our study has several strengths. First, it is a population-based study with a representative sample of the Portuguese adult population, minimizing the risk of biased selection. Second, we compared HRQoL in a large sample of adults with spondyloarthritis, CLBP, or no RMDs. To our knowledge, this has never been done before.

Our study also has limitations. First, the number of spondyloarthritis participants was small and the disease type was heterogeneous (i.e., including both the axial and peripheral forms) as a result of the low prevalence of spondyloarthritis (1.6%) in the Portuguese population [83]. Also, the study methodology and population recruitment led to a smaller group of adults without RMDs than the CLBP group. Nevertheless, this allowed us to include a control group and make direct comparisons of HRQoL between the participants without RMDs and those with spondyloarthritis/CLBP without extrapolating the necessary data from other studies. Second, we used PhGA as a surrogate marker of disease activity instead of a disease-specific validated score, like BASDAI or ASDAS. Although this is not ideal, previous research has demonstrated that this measure is a simple and reliable instrument to evaluate disease activity in an outpatient setting, using a cut-off of ≤ 20 mm to define inactive disease [84]. Third, the cross-sectional design limits the prognostic value of our analyses and does not allow us to draw conclusions about causal relationships. Only a future longitudinal study that follows up with these patients will allow us to draw more robust conclusions.

Conclusions

In summary, we have shown that spondyloarthritis and CLBP patients experience significantly impaired HRQoL compared with a population without RMDs. However, we found no differences between spondyloarthritis and CLBP in the physical, mental, and social aspects of HRQoL. Our data also suggest that disease activity, exercise, and the presence of chronic noncommunicable diseases are important determinants of HRQoL in spondyloarthritis patients. Considering that one of the primary goals of treating spondyloarthritis is to maximize long-term HRQoL, we should pay careful attention to controlling disease activity, identifying and treating chronic noncommunicable diseases, and promoting regular physical exercise from disease onset. Our study further highlights several important interventions that can target modifiable factors associated with HRQoL in CLBP patients: identifying and treating chronic

noncommunicable diseases, promoting weight reduction and regular physical exercise, and assessing and controlling low back pain with pharmacological and non-pharmacological interventions.

These results are valuable for rheumatologists, as they enable a better understanding of the burden associated with CLBP and spondyloarthritis, as well as for policymakers and national healthcare systems, as they can inform adjustments to future health plans.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11136-022-03274-0>.

Acknowledgements We would like to acknowledge the contribution of all members of EpiReumaPt study group. Helena Santos further acknowledges the support from Sociedade Portuguesa de Reumatologia.

Author contributions All authors contributed to the study conception and design. Materials preparation, data collection, and analysis were performed by HS, ARH, and AMR. The first draft of the manuscript was written by HS, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding All authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Declarations

Conflict of interest The authors declare that they have no conflict of interest, financial or non-financial, related to this research.

Ethical approval This study was performed in line with the principles of the Declaration of Helsinki, and approval was granted by the Ethics Committee of NOVA Medical School (n°123/2020/CEFCM).

Consent to participate Informed consent was obtained from all individual participants included in the study.

References

1. Beaudart, C., Biver, E., Bruyère, O., Cooper, C., Al-Daghri, N., Reginster, J. Y., & Rizzoli, R. (2018). Assessment of quality of life in musculo-skeletal health Europe PMC funders group. *Aging Clinical and Experimental Research*, 30(5), 413–418. <https://doi.org/10.1007/s40520-017-0794-8>. **Assessment**
2. Kotsis, K., Voulgari, P. V., Drosos, A. A., Carvalho, A. F., & Hyphantis, T. (2014). Health-related quality of life in patients with ankylosing spondylitis: A comprehensive review. *Expert Review of Pharmacoeconomics and Outcomes Research*, 14(6), 857–872. <https://doi.org/10.1586/14737167.2014.957679>
3. Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coggeshall, M., Cornaby, L., Dandona, L., Dicker, D. J., Dilegge, T., Erskine, H. E., Ferrari, A. J., Fitzmaurice, C., Fleming, T., et al. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. *The Lancet*, 388(10053), 1545–1602. [https://doi.org/10.1016/S0140-6736\(16\)31678-6](https://doi.org/10.1016/S0140-6736(16)31678-6)
4. Sebbag, E., Felten, R., Sagez, F., Sibilia, J., Devilliers, H., & Arnaud, L. (2019). The world-wide burden of musculoskeletal diseases: A systematic analysis of the World Health Organization Burden of Diseases Database. *Annals of the Rheumatic Diseases*, 78(6), 844–848. <https://doi.org/10.1136/annrheumdis-2019-215142>
5. Salaffi, F., Di Carlo, M., Carotti, M., Farah, S., Ciapetti, A., & Gutierrez, M. (2018). The impact of different rheumatic diseases on health-related quality of life: A comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values. *Acta Biomedica*, 89(4), 541–557. <https://doi.org/10.23750/abm.v89i4.7298>
6. Branco, J. C., Rodrigues, A. M., Gouveia, N., Eusébio, M., Ramiro, S., Machado, P. M., da Costa, L. P., Mourão, A. F., Silva, I., Lares, P., Sepriano, A., Araújo, F., Gonçalves, S., Coelho, P. S., Tavares, V., Cero, J., Mendes, J. M., Carmona, L., Canhão, H., et al. (2016). Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt—A national health survey. *RMD Open*, 2(1), e000166. <https://doi.org/10.1136/rmdopen-2015-000166>
7. Roux, C. H., Guillemin, F., Boini, S., Longuetaud, F., Arnault, N., Hercberg, S., & Briançon, S. (2005). Impact of musculoskeletal disorders on quality of life: An inception cohort study. *Annals of the Rheumatic Diseases*, 64(4), 606–611. <https://doi.org/10.1136/ard.2004.020784>
8. Carmona, L., Ballina, J., Gabriel, R., & Laffon, A. (2001). The burden of musculoskeletal diseases in the general population of Spain: Results from a national survey. *Annals of the Rheumatic Diseases*, 60(11), 1040–1045. <https://doi.org/10.1136/ard.60.11.1040>
9. Picavet, H. S. J., & Hoeymans, N. (2004). Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. *Annals of the Rheumatic Diseases*, 63(6), 723–729. <https://doi.org/10.1136/ard.2003.010769>
10. Saarni, S. I., Härkänen, T., Sintonen, H., Suvisaari, J., Koskinen, S., Aromaa, A., & Lönnqvist, J. (2006). The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. *Quality of Life Research*, 15(8), 1403–1414. <https://doi.org/10.1007/s11136-006-0020-1>
11. Sprangers, M. A. G., de Regt, E. B., Andries, F., van Agt, H. M. E., Bijl, R. V., de Boer, J. B., Foets, M., Hoeymans, N., Jacobs, A. E., Kempen, G. I. J. M., Miedema, H. S., Tijhuis, M. A. R., & de Haes, H. C. J. M. (2000). Which chronic conditions are associated with better or poorer quality of life? *Journal of Clinical Epidemiology*, 53(9), 895–907. [https://doi.org/10.1016/S0895-4356\(00\)00204-3](https://doi.org/10.1016/S0895-4356(00)00204-3)
12. Lyons, R. A., Lo, S. V., & Littlepage, B. N. C. (1994). Comparative health status of patients with 11 common illnesses in Wales. *Journal of Epidemiology and Community Health*, 48(4), 388–390. <https://doi.org/10.1136/jech.48.4.388>
13. Johnson, J. A., & Coons, S. J. (1998). Comparison of the EQ-5D and SF-12 in an adult US sample. *Quality of Life Research*, 7(2), 155–166. <https://doi.org/10.1023/A:1008809610703>
14. Kempen, G. I. J. M., Ormel, J., Brilman, E. I., & Relyveld, J. (1997). Adaptive responses among Dutch elderly: The impact of eight chronic medical conditions on health-related quality of life. *American Journal of Public Health*, 87(1), 38–44. <https://doi.org/10.2105/AJPH.87.1.38>
15. Hartvigsen, J., Hancock, M. J., Kongsted, A., Louw, Q., Ferreira, M. L., Genevay, S., Hoy, D., Karppinen, J., Pransky, G., Sieper, J., Smeets, R. J., Underwood, M., Buchbinder, R., Hartvigsen, J., Cherklin, D., Foster, N. E., Maher, C. G., Underwood, M., van Tulder, M., et al. (2018). What low back pain is and why we need to pay attention. *The Lancet*, 391(10137), 2356–2367. [https://doi.org/10.1016/S0140-6736\(18\)30480-X](https://doi.org/10.1016/S0140-6736(18)30480-X)

16. Gouveia, N., Rodrigues, A., Eusébio, M., Ramiro, S., Machado, P., Canhão, H., & Branco, J. C. (2016). Prevalence and social burden of active chronic low back pain in the adult Portuguese population: Results from a national survey. *Rheumatology International*, 36(2), 183–197. <https://doi.org/10.1007/s00296-015-3398-7>
17. Husky, M. M., Ferdous Farin, F., Compagnone, P., Fermanian, C., & Kovess-Masfety, V. (2018). Chronic back pain and its association with quality of life in a large French population survey. *Health and quality of life outcomes*, 16(1), 195. <https://doi.org/10.1186/s12955-018-1018-4>
18. Perrot, S., Doane, M. J., Jaffe, D. H., Dragon, E., Abraham, L., Viktrup, L., Bushmakina, A. G., Capelleri, J. C., & Conaghan, P. G. (2022). Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countries. *Pain Practice*, 22(3), 359–371. <https://doi.org/10.1111/papr.13093>
19. Cedraschi, C., Luthy, C., Allaz, A. F., Herrmann, F. R., & Ludwig, C. (2016). Low back pain and health-related quality of life in community-dwelling older adults. *European Spine Journal*, 25(9), 2822–2832. <https://doi.org/10.1007/s00586-016-4483-7>
20. Járomi, M., Szilágyi, B., Velényi, A., Leidecker, E., Raposa, B. L., Hock, M., Bauman, P., Ács, P., & Makai, A. (2021). Assessment of health-related quality of life and patient's knowledge in chronic non-specific low back pain. *BMC Public Health*, 21(Suppl 1), 1–8. <https://doi.org/10.1186/s12889-020-09506-7>
21. Fredheim, O. M. S., Kaasa, S., Fayers, P., Saltnes, T., Jordhøy, M., & Borchgrevink, P. C. (2008). Chronic non-malignant pain patients report as poor health-related quality of life as palliative cancer patients. *Acta Anaesthesiologica Scandinavica*, 52(1), 143–148. <https://doi.org/10.1111/j.1399-6576.2007.01524.x>
22. Rudwaleit, M., van der Heijde, D., Landewe, R., Listing, J., Akkoc, N., Brandt, J., Braun, J., Chou, C. T., Collantes-Estevez, E., Dougados, M., Huang, F., Gu, J., Khan, M. A., Kirazli, Y., Maksymowych, W. P., Mielants, H., Sorensen, I. J., Ozgocmen, S., Roussou, E., et al. (2009). The development of Assessment of spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. *Annals of the Rheumatic Diseases*, 68(6), 777–783. <https://doi.org/10.1136/ard.2009.108233>
23. Rudwaleit, M., van der Heijde, D., Landewe, R., Akkoc, N., Brandt, J., Chou, C. T., Dougados, M., Huang, F., Gu, J., Kirazli, Y., Van den Bosch, F., Olivieri, I., Roussou, E., Scarpato, S., Sorensen, I. J., Valle-Onate, R., Weber, U., Wei, J., & Sieper, J. (2011). The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Annals of the Rheumatic Diseases*, 70(1), 25–31. <https://doi.org/10.1136/ard.2010.133645>
24. López-Medina, C., Molto, A., Sieper, J., Duruöz, T., Kiltz, U., Elzorkany, B., Hajjaj-Hassouni, N., Burgos-Vargas, R., Maldonado-Cocco, J., Ziade, N., Gavali, M., Navarro-Compan, V., Luo, S.-F., Monti, S., Tae-Jong, K., Kishimoto, M., Pimentel-Santos, F. M., Gu, J., Schiotis, R., et al. (2021). Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: Results of the worldwide, cross-sectional ASAS-PerSpA study. *RMD Open*, 7(1), e001450. <https://doi.org/10.1136/rmdopen-2020-001450>
25. Yang, X., Fan, D., Xia, Q., Wang, M., Zhang, X., Li, X., Xu, S., & Pan, F. (2016). The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: A systematic review and meta-analysis. *Quality of Life Research*, 25, 2711–2723. <https://doi.org/10.1007/s11136-016-1345-z>
26. Van Den Bosch, F., Mease, P. J., Sieper, J., Baeten, D. L., Xia, Y., Chen, S., Pangan, A. L., & Song, I. H. (2018). Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ability-2. *RMD Open*, 4(1), 1–10. <https://doi.org/10.1136/rmdopen-2017-000566>
27. Omayolu, N., Omayolu, O., & Karadag, G. (2011). Health-related quality of life in ankylosing spondylitis, fibromyalgia syndrome, and rheumatoid arthritis: A comparison with a selected sample of healthy individuals. *Clinical Rheumatology*, 30(5), 655–664. <https://doi.org/10.1007/s10067-010-1604-2>
28. López-Medina, C., Garrido-Castro, J. L., Castro-Jiménez, J., González-Navas, C., Calvo-Gutiérrez, J., Castro-Villegas, M. C., Ortega-Castro, R., Escudero-Contreras, A., Font-Ugalde, P., & Collantes-Estévez, E. (2018). Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. *Clinical Rheumatology*, 37(6), 1581–1588. <https://doi.org/10.1007/s10067-018-4112-4>
29. Macfarlane, G. J., Rotariu, O., Jones, G. T., Pathan, E., & Dean, L. E. (2020). Determining factors related to poor quality of life in patients with axial spondyloarthritis: Results from the British Society for Rheumatology Biologics Register (BSRBR-AS). *Annals of the Rheumatic Diseases*, 79(2), 202–208. <https://doi.org/10.1136/annrheumdis-2019-216143>
30. Rosenbaum, J. T., Pisenti, L., Park, Y., & Howard, R. A. (2019). Insight into the quality of life of patients with ankylosing spondylitis: Real-world data from a US-based life impact survey. *Rheumatology and Therapy*, 6(3), 353–367. <https://doi.org/10.1007/s40744-019-0160-8>
31. Boonen, A., & Van Der Linden, S. M. (2006). The burden of ankylosing spondylitis. *Journal of Rheumatology*, 33(SUPPL. 78), 4–11.
32. Haugeberg, G., Michelsen, B., & Kavanaugh, A. (2020). Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. *RMD Open*, 6(1), 1–9. <https://doi.org/10.1136/rmdopen-2020-001223>
33. van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., van Gaalen, F., Géher, P., van der Horst-Bruinsma, I., Inman, R. D., Jongkees, M., Kiltz, U., Kvien, T. K., Machado, P. M., Marzo-Ortega, H., et al. (2017). 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Annals of the Rheumatic Diseases*, 76(6), 978–991. <https://doi.org/10.1136/annrheumdis-2016-210770>
34. Ward, M. M., Deodhar, A., Akl, E. A., Lui, A., Ermann, J., Gensler, L. S., Smith, J. A., Borenstein, D., Hiratzka, J., Weiss, P. F., Inman, R. D., Majithia, V., Haroon, N., Maksymowych, W. P., Joyce, J., Clark, B. M., Colbert, R. A., Figgie, M. P., Hallegua, D. S., et al. (2016). American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis and Rheumatology*, 68(2), 282–298. <https://doi.org/10.1002/art.39298>
35. National Institute for Health and Care Excellence. (2016). Low back pain and sciatica in over 16s: assessment and management (NG59). *Nice*, 2016, 1–18.
36. Wambeke, P., Desomer, A., Ailliet, L., & Demoulin, C. (2017). Low back pain and radicular pain: Assessment and management, 2017.
37. Stochkendahl, M. J., Kjaer, P., Hartvigsen, J., Kongsted, A., Aaboe, J., Andersen, M., Andersen, M. Ø., Fournier, G., Højgaard, B., Jensen, M. B., Jensen, L. D., Karbo, T., Kirkeskov, L., Melbye, M., Morsel-Carlsen, L., Nordsteen, J., Palsson, T. S., Rasti, Z., Silbye, P. F., et al. (2018). National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. *European Spine Journal*, 27(1), 60–75. <https://doi.org/10.1007/s00586-017-5099-2>
38. Kreis, S., Molto, A., Bailly, F., Dadoun, S., Fabre, S., Rein, C., Gossec, L., Hudry, C., Zenasni, F., Rozenberg, S., Pertuiset, E.,

- Fautrel, B., & Gossec, L. (2015). Relationship between optimism and quality of life in patients with two chronic rheumatic diseases: Axial spondyloarthritis and chronic low back pain: A cross sectional study of 288 patients. *Health and Quality of Life Outcomes*, 13(1), 1–6. <https://doi.org/10.1186/s12955-015-0268-7>
39. Rodrigues, A. M., Gouveia, N., da Costa, L. P., Eusébio, M., Ramiro, S., Machado, P., Mourão, A. F., Silva, I., Laires, P., Sepriano, A., Araújo, F., Coelho, P. S., Gonçalves, S., Zhao, A., Fonseca, J. E., de Almeida, J. M. C., Tavares, V., da Silva, J. A. P., Barros, H., et al. (2015). EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: A detailed view of the methodology. *Acta reumatologica portuguesa*, 40(2), 110–124.
 40. Gouveia, N., Rodrigues, A. M., Ramiro, S., Machado, P., da Costa, L. P., Mourão, A. F., Silva, I., Rego, T., Laires, P., André, R., Mauricio, L., Romeu, J. C., Tavares, V., Cerol, J., Canhão, H., & Branco, J. C. (2015). EpiReumaPt: How to perform a national population based study—A practical guide. *Acta reumatologica portuguesa*, 40(2), 128–136.
 41. Ferreira, L. N., Ferreira, P. L., Pereira, L. N., & Oppe, M. (2014). The valuation of the EQ-5D in Portugal. *Quality of Life Research*, 23(2), 413–423. <https://doi.org/10.1007/s11136-013-0448-z>
 42. Group, T. E. (1990). EuroQol—A new facility for the measurement of health-related quality of life. *Health Policy*, 16(3), 199–208. [https://doi.org/10.1016/0168-8510\(90\)90421-9](https://doi.org/10.1016/0168-8510(90)90421-9)
 43. Ferreira, L. N., Ferreira, P. L., Pereira, L. N., & Oppe, M. (2014). EQ-5D Portuguese population norms. *Quality of Life Research*, 23(2), 425–430. <https://doi.org/10.1007/s11136-013-0488-4>
 44. Wolfe, F., & Hawley, D. J. (1997). Measurement of the quality of life in rheumatic disorders using the EuroQol. *British Journal of Rheumatology*, 36(7), 786–793. <https://doi.org/10.1093/rheumatology/36.7.786>
 45. Leung, Y. Y. (2020). Validity and reliability of EQ-5D-5L among patients with axial spondyloarthritis in Singapore. *European Journal of Rheumatology*, 7(2), 71–78. <https://doi.org/10.5152/eurjrheum.2020.19043>
 46. Tsang, H. H. L., Cheung, J. P. Y., Wong, C. K. H., Cheung, P. W. H., Lau, C. S., & Chung, H. Y. (2019). Psychometric validation of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with spondyloarthritis. *Arthritis Research and Therapy*, 21(1), 1–14. <https://doi.org/10.1186/s13075-019-1826-x>
 47. Tsang, H. H. L., Wong, C. K. H., Cheung, P. W. H., Lau, C. S., Chung, H. Y., & Cheung, J. P. Y. (2021). Responsiveness of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with spondyloarthritis. *BMC Musculoskeletal Disorders*, 22(1), 1–14. <https://doi.org/10.1186/s12891-021-04315-4>
 48. Garratt, A. M., Furunes, H., Hellum, C., Solberg, T., Brox, J. I., Storheim, K., & Johnsen, L. G. (2021). Evaluation of the EQ-5D-3L and 5L versions in low back pain patients. *Health and Quality of Life Outcomes*, 19(1), 1–9. <https://doi.org/10.1186/s12955-021-01792-y>
 49. Cheung, P. W. H., Wong, C. K. H., & Cheung, J. P. Y. (2019). Differential psychometric properties of EuroQoL 5-dimension 5-level and short-form 6-dimension utility measures in low back pain. *Spine*, 44(11), E679–E686. <https://doi.org/10.1097/BRS.0000000000002939>
 50. Poder, T. G., Wang, L., & Carrier, N. (2020). EQ-5D-5L and SF-6Dv2 utility scores in people living with chronic low back pain: A survey from Quebec. *British Medical Journal Open*, 10(9), e035722. <https://doi.org/10.1136/bmjopen-2019-035722>
 51. Salaffi, F., Carotti, M., Gasparini, S., Intorcchia, M., & Grassi, W. (2009). The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: A comparison with a selected sample of healthy people. *Health and Quality of Life Outcomes*, 7, 1–12. <https://doi.org/10.1186/1477-7525-7-25>
 52. Hamdi, W., Azzouz, D., Ghannouchi, M. M., Haouel, M., Kochbati, S., Saadellaoui, K., Hmida, A. B., Zouari, B., & Kchir, M. (2012). Health-related quality of life assessment on 100 Tunisian patients with ankylosing spondylitis using the SF-36 survey. *Oman Medical Journal*, 27(6), 455–460. <https://doi.org/10.5001/omj.2012.109>
 53. Gouveia, N., Rodrigues, A., Ramiro, S., Eusébio, M., Machado, P. M., Canhão, H., & Branco, J. C. (2017). The use of analgesic and other pain-relief drugs to manage chronic low back pain: Results from a national survey. *Pain Practice*, 17(3), 353–365. <https://doi.org/10.1111/papr.12455>
 54. Husted, J. A., Gladman, D. D., Farewell, V. T., & Cook, R. J. (2001). Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. *Arthritis Care and Research*, 45(2), 151–158. [https://doi.org/10.1002/1529-0131\(200104\)45:2%3c151::aid-anr168%3e3.0.co;2-t](https://doi.org/10.1002/1529-0131(200104)45:2%3c151::aid-anr168%3e3.0.co;2-t)
 55. Chorus, A. M. J., Miedema, H. S., Boonen, A., & Van Der Linden, S. (2003). Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. *Annals of the Rheumatic Diseases*, 62(12), 1178–1184. <https://doi.org/10.1136/ard.2002.004861>
 56. Hyphantis, T., Kotsis, K., Tsifetaki, N., Creed, F., Drosos, A. A., Carvalho, A. F., & Voulgari, P. V. (2013). The relationship between depressive symptoms, illness perceptions and quality of life in ankylosing spondylitis in comparison to rheumatoid arthritis. *Clinical Rheumatology*, 32(5), 635–644. <https://doi.org/10.1007/s10067-012-2162-6>
 57. Fernández-Carballido, C., Navarro-Compán, V., Castillo-Gallego, C., Castro-Villegas, M. C., Collantes-Estévez, E., de Miguel, E., & Clínic, H. (2017). Disease activity as a major determinant of quality of life and physical function in patients with early axial spondyloarthritis. *Arthritis Care and Research*, 69(1), 150–155. <https://doi.org/10.1002/acr.22908>
 58. Machado, P., Landewé, R., Braun, J., Hermann, K. G. A., Baraliakos, X., Baker, D., Hsu, B., & Van Der Heijde, D. (2011). A stratified model for health outcomes in ankylosing spondylitis. *Annals of the Rheumatic Diseases*, 70(10), 1758–1764. <https://doi.org/10.1136/ard.2011.150037>
 59. Fitzgerald, G., Gallagher, P., & O'Shea, F. D. (2020). Multimorbidity in axial spondyloarthropathy and its association with disease outcomes: results from the ankylosing spondylitis registry of Ireland cohort. *The Journal of Rheumatology*, 47(2), 218–226. <https://doi.org/10.3899/jrheum.181415>
 60. Moltó, A., Etcheto, A., van der Heijde, D., Landewé, R., van den Bosch, F., Molano, W. B., Burgos-Vargas, R., Cheung, P. P., Collantes-Estévez, E., Deodhar, A., El-Zorkany, B., Erdes, S., Jieruo, G., Hajjaj-Hassouni, N., Kiltz, U., Kim, T.-H., Kishimoto, M., Luo, S.-F., Machado, P. M., et al. (2016). Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study. *Annals of the Rheumatic Diseases*, 75(6), 1016–1023. <https://doi.org/10.1136/annrheumdis-2015-208174>
 61. Zhao, S. S., Robertson, S., Reich, T., Harrison, N. L., Moots, R. J., & Goodson, N. J. (2020). Prevalence and impact of comorbidities in axial spondyloarthritis: Systematic review and meta-analysis. *Revmatologia (Bulgaria)*, 59, IV47–IV57. <https://doi.org/10.1093/rheumatology/keaa246>
 62. Santos, H., Brophy, S., & Calin, A. (1998). Exercise in ankylosing spondylitis: how much is optimum? *The Journal of rheumatology*, 25(11), 2156–2160.
 63. Patterson, S. L., Reveille, J. D., Lee, M. J., Ward, M. M., Rahbar, M. H., Brown, M. A., Weisman, M. H., & Gensler, L. S. (2014). Better outcomes in ankylosing spondylitis: the synergistic association between exercise and tumor necrosis factor inhibitors. *Arthritis & rheumatology*, 66(10), S250–S251.
 64. Jung, S. H., Kwon, O. Y., Yi, C. H., Cho, S. H., Jeon, H. S., Weon, J. H., & Hwang, U. J. (2018). Predictors of dysfunction and health-related quality of life in the flexion pattern subgroup

- of patients with chronic lower back pain: The STROBE study. *Medicine (United States)*, 97(29), e11363. <https://doi.org/10.1097/MD.00000000000011363>
65. Uchmanowicz, I., Kołtuniuk, A., Stepień, A., Uchmanowicz, B., & Rosińczuk, J. (2019). The influence of sleep disorders on the quality of life in patients with chronic low back pain. *Scandinavian Journal of Caring Sciences*, 33(1), 119–127. <https://doi.org/10.1111/scs.12610>
 66. Stefane, T., Dos Santos, A. M., Marinovic, A., & Hortense, P. (2013). Chronic low back pain: Pain intensity, disability and quality of life. *ACTA Paulista de Enfermagem*, 26(1), 14–20. <https://doi.org/10.1590/S0103-21002013000100004>
 67. Aminde, J. A., Aminde, L. N., Bija, M. D., Lekpa, F. K., Kwedi, F. M., Yenshu, E. V., & Chichom, A. M. (2020). Health-related quality of life and its determinants in patients with chronic low back pain at a tertiary hospital in Cameroon: A cross-sectional study. *British Medical Journal Open*. <https://doi.org/10.1136/bmjopen-2019-035445>
 68. Darzi, M. T., Pourhadi, S., Hosseinzadeh, S., Ahmadi, M. H., & Dadian, M. (2014). Comparison of quality of life in low back pain patients and healthy subjects by using WHOQOL-BREF. *Journal of Back and Musculoskeletal Rehabilitation*, 27(4), 507–512. <https://doi.org/10.3233/BMR-140474>
 69. Klemenc-Ketis, Z. (2011). Predictors of health-related quality of life and disability in patients with chronic non-specific low back pain. *Zdravniški vestnik*, 80(5), 379–385.
 70. Hadziomerovic, A. M., Vilic, M., Ajnadzic, N., Jaganjac, A., & Memisevic, H. (2017). The effects of age and gender on the quality of life of people with chronic back pain in Bosnia and Herzegovina. *Disability, CBR and Inclusive Development*, 28(2), 129–138. <https://doi.org/10.5463/DCID.v28i2.631>
 71. Wettstein, M., Eich, W., Bieber, C., & Tesarz, J. (2019). Pain intensity, disability, and quality of life in patients with chronic low back pain: Does age matter? *Pain Medicine (United States)*, 20(3), 464–475. <https://doi.org/10.1093/pm/pny062>
 72. Mutubuki, E. N., Beljon, Y., Maas, E. T., Huygen, F. J. P. M., Ostelo, R. W. J. G., van Tulder, M. W., & van Dongen, J. M. (2020). The longitudinal relationships between pain severity and disability versus health-related quality of life and costs among chronic low back pain patients. *Quality of Life Research*, 29(1), 275–287. <https://doi.org/10.1007/s11136-019-02302-w>
 73. Guclu, D. G., Guclu, O., Ozaner, A., Senormanci, O., & Konkan, R. (2012). The relationship between disability, quality of life and fear-avoidance beliefs in patients with chronic low back pain. *Turkish Neurosurgery*, 22(6), 724–731. <https://doi.org/10.5137/1019-5149.JTN.6156-12.1>
 74. Nikiphorou, E., Ramiro, S., van der Heijde, D., Norton, S., Moltó, A., Dougados, M., van den Bosch, F., & Landewé, R. (2018). Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: Results from the assessment of spondyloarthritis international society comorbidities in spondyloarthritis study. *Arthritis Care and Research*, 70(8), 1257–1262. <https://doi.org/10.1002/acr.23468>
 75. Zhao, S. S., Radner, H., Siebert, S., Duffield, S. J., Thong, D., Hughes, D. M., Moots, R. J., Solomon, D. H., & Goodson, N. J. (2019). Comorbidity burden in axial spondyloarthritis: A cluster analysis. *Rheumatology (United Kingdom)*, 58(10), 1746–1754. <https://doi.org/10.1093/rheumatology/kez119>
 76. Heuch, I., Heuch, I., Hagen, K., & Zwart, J. A. (2013). Body mass index as a risk factor for developing chronic low back pain: A follow-up in the nord-trøndelag health study. *Spine*, 38(2), 133–139. <https://doi.org/10.1097/BRS.0b013e3182647af2>
 77. Heuch, I., Heuch, I., Hagen, K., & Zwart, J. A. (2015). A comparison of anthropometric measures for assessing the association between body size and risk of chronic low back pain: The HUNT study. *PLoS ONE*, 10(10), 1–15. <https://doi.org/10.1371/journal.pone.0141268>
 78. Fontaine, K. R., & Barofsky, I. (2001). Obesity and health-related quality of life. *Obesity Reviews*, 2(3), 173–82. <https://doi.org/10.1046/j.1467-789x.2001.00032.x>
 79. Kolotkin, R. L., & Andersen, J. R. (2017). A systematic review of reviews: Exploring the relationship between obesity, weight loss and health-related quality of life. *Clinical Obesity*, 7(5), 273–289. <https://doi.org/10.1111/cob.12203>
 80. Ugochukwu, C., Bagot, K. S., Delaloye, S., Pi, S., Vien, L., Garvey, T., Bolotaulo, N. I., Kumar, N., & Ishak, W. W. (2013). The importance of quality of life in patients with alcohol abuse and dependence. *Harvard Review of Psychiatry*, 21(1), 1–17. <https://doi.org/10.1097/HRP.0b013e31827fd8aa>
 81. Searle, A., Spink, M., Ho, A., & Chuter, V. (2015). Exercise interventions for the treatment of chronic low back pain: A systematic review and meta-analysis of randomised controlled trials. *Clinical Rehabilitation*, 29(12), 1155–1167. <https://doi.org/10.1177/0269215515570379>
 82. Schaller, A., Dejonghe, L., Haastert, B., & Froboese, I. (2015). Physical activity and health-related quality of life in chronic low back pain patients: A cross-sectional study Rehabilitation, physical therapy and occupational health. *BMC Musculoskeletal Disorders*, 16(1), 1–8. <https://doi.org/10.1186/s12891-015-0527-0>
 83. Rodrigues, J., Rodrigues, A. M., Dias, S. S., Sousa, R. D., Branco, J. C., & Canhão, H. (2019). Psoriatic arthritis and ankylosing spondylitis impact on health-related quality of life and working life: A comparative population-based study. *Acta Reumatologica Portuguesa*. Retrieved from <http://www.ncbi.nlm.nih.gov/pub-med/32008031>
 84. Lubrano, E., Perrotta, F. M., Parsons, W. J., & Marchesoni, A. (2015). Patient's global assessment as an outcome measure for psoriatic arthritis in clinical practice: A surrogate for measuring low disease activity? *Journal of Rheumatology*, 42(12), 2332–2338. <https://doi.org/10.3899/jrheum.150595>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.